AML

Four things payers need to know about acute myeloid leukemiaPhysicians need to be able to move quickly to care for patients with AML, and they need to have payers on board.
Oral specialty drug options on the horizon
Oral specialty drug options on the horizonAs more specialty drugs are approved, cost control strategies are key.
FDA pipeline previewComplete response, priority review, breakthrough therapy designations, fast-track designations, orphan drug designations, first-time generic approval